Azitra shares ex‑vivo skin study results and pauses ATM share sales
Azitra Inc. reported that its ATR‑COSF cosmetic candidate reduced fine lines by up to 50% after 48 hours in a 2% formulation and improved elasticity with a 4% formulation in ex‑vivo skin explants. The company will present detailed data at the BIO‑Europe conference on November 10, 2026 and expects first‑in‑human results from a 30‑subject study by year‑end. CEO Francisco Salva noted that institutional investors can commit an additional $5.25 million to $10.5 million from earlier instruments, while the firm paused its ATM sales program after raising $126 from 1,000 shares.
Why it matters
The positive study data could boost market interest in Azitra’s dermatology pipeline, while the ATM pause limits immediate cash‑raising capacity. The company’s invitation for extra $5.25‑$10.5 million investment may offset the financing gap.
Key facts
- 1A 2% ATR‑COSF formulation reduced fine lines and wrinkles by approximately 50% at 48 hours in ex‑vivo skin samples. investing.com
- 2A 4% ATR‑COSF formulation improved elasticity parameters in face‑lift skin samples. investing.com
- 3Azitra will present detailed data at the BIO‑Europe conference in Cologne on November 10, 2026. investing.com
- 4The company anticipates first‑in‑human results from a study of about 30 subjects by year‑end. investing.com
- 5CEO Francisco Salva said institutional investors can invest an additional $5.25 million to $10.5 million from earlier financial instruments. investing.com
- 6Azitra paused its ATM sales program after raising $126 from the sale of 1,000 shares. tradingview.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.